Effect of nateglinide on the incidence of diabetes and cardiovascular events. by Holman, Rury R et al.
n engl j med 362;2 nejm.org april 22, 2010 1463
The new england  
journal of medicine
established in 1812 april 22, 2010 vol. 362 no. 16
Effect of Nateglinide on the Incidence of Diabetes  
and Cardiovascular Events
The NAVIGATOR Study Group*
A BS TR AC T
The authors are listed in the Appendix. 
Address reprint requests to Dr. Rury R. 
Holman at the Diabetes Trials Unit, Ox-
ford Centre for Diabetes, Endocrinology, 
and Metabolism, Churchill Hospital, Ox-
ford OX3 7LJ, United Kingdom, or at rury 
.holman@dtu.ox.ac.uk.
*The names of the investigators and 
members of the committees in the Na-
teglinide and Valsartan in Impaired Glu-
cose Tolerance Outcomes Research 
(NAVIGATOR) Study Group are listed in 
Supplementary Appendix 1, available with 
the full text of this article at NEJM.org.
This article (10.1056/NEJMoa1001122) was 
published on March 14, 2010, and was up-
dated on March 29, 2010, at NEJM.org.
N Engl J Med 2010;362:1463-76.
Copyright © 2010 Massachusetts Medical Society.
Background
The ability of short-acting insulin secretagogues to reduce the risk of diabetes or 
cardiovascular events in people with impaired glucose tolerance is unknown.
Methods
In a double-blind, randomized clinical trial, we assigned 9306 participants with 
impaired glucose tolerance and either cardiovascular disease or cardiovascular risk 
factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 
factorial design with valsartan or placebo, in addition to participation in a lifestyle 
modification program. We followed the participants for a median of 5.0 years for 
incident diabetes (and a median of 6.5 years for vital status). We evaluated the effect 
of nateglinide on the occurrence of three coprimary outcomes: the development of 
diabetes; a core cardiovascular outcome that was a composite of death from cardio-
vascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization 
for heart failure; and an extended cardiovascular outcome that was a composite of 
the individual components of the core composite cardiovascular outcome, hospital-
ization for unstable angina, or arterial revascularization.
Results
After adjustment for multiple testing, nateglinide, as compared with placebo, did 
not significantly reduce the cumulative incidence of diabetes (36% and 34%, respec-
tively; hazard ratio, 1.07; 95% confidence interval [CI], 1.00 to 1.15; P = 0.05), the core 
composite cardiovascular outcome (7.9% and 8.3%, respectively; hazard ratio, 0.94, 
95% CI, 0.82 to 1.09; P = 0.43), or the extended composite cardiovascular outcome 
(14.2% and 15.2%, respectively; hazard ratio, 0.93, 95% CI, 0.83 to 1.03; P = 0.16). 
Nateglinide did, however, increase the risk of hypoglycemia.
Conclusions
Among persons with impaired glucose tolerance and established cardiovascular dis-
ease or cardiovascular risk factors, assignment to nateglinide for 5 years did not re-
duce the incidence of diabetes or the coprimary composite cardiovascular outcomes. 
(ClinicalTrials.gov number, NCT00097786.)
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Persons with impaired glucose tol-erance are at increased risk for type 2 dia-betes mellitus and cardiovascular disease1-3; 
therefore, treatments that might reduce the inci-
dence of diabetes and associated cardiovascular 
disease and death are potentially important.3 The 
risk of diabetes is reduced with lifestyle interven-
tions that involve increasing physical activity and 
reducing weight  4-6 and with metformin,6 acar-
bose,7 or rosiglitazone8 therapy, but no trials to 
date have been powered to consider cardiovascu-
lar outcomes.
Among persons with type 2 diabetes, reducing 
glycemia results in a small reduction in the risk 
of major macrovascular events.9 Glucose levels af-
ter a glucose challenge, however, are more closely 
associated with cardiovascular risk than are fast-
ing glucose levels,2 suggesting that postprandi-
al glycemia may be a distinct therapeutic target. 
Lowering postprandial glucose levels with the 
alpha-glucosidase inhibitor acarbose has been re-
ported to decrease the risk of myocardial infarc-
tion among persons with impaired glucose tol-
erance.10
In a large, prospective study involving persons 
with impaired glucose tolerance and cardiovascu-
lar disease or cardiovascular risk factors, we evalu-
ated an alternative postprandial glucose-lower-
ing approach that used the short-acting insulin 
secretagogue nateglinide, in addition to a lifestyle 
modification program. The aim of the Nateglin-
ide and Valsartan in Impaired Glucose Tolerance 
Outcomes Research (NAVIGATOR) trial11 was to 
determine whether the risk of diabetes and car-




The trial was approved by the ethics committee 
at each participating center, and all participants 
provided written informed consent. The study was 
sponsored by Novartis Pharma, was designed by 
the sponsor in collaboration with an academic 
executive committee, and was monitored by an 
independent data and safety monitoring commit-
tee (see Supplementary Appendix 1, available 
with the full text of this article at NEJM.org).11 
Data were collected, managed, and analyzed by 
the sponsor, with oversight by the executive com-
mittee, and analyses were replicated by an inde-
pendent academic statistician from the London 
School of Hygiene and Tropical Medicine. The 
manuscript was prepared by the writing group 
(see Section 1 in Supplementary Appendix 1), 
whose members had unrestricted access to the 
data, and was revised subsequently by all the au-
thors. All the authors made the decision to sub-
mit the manuscript for publication and assume 
responsibility for the accuracy and completeness 
of the data. The NAVIGATOR trial protocol is avail-
able in Supplementary Appendix 2.
Study Participants
Subjects were eligible for inclusion in the study if 
they had impaired glucose tolerance,3 a fasting 
plasma glucose concentration of at least 95 mg per 
deciliter (5.3 mmol per liter) but less than 126 mg 
per deciliter (7.0 mmol per liter), and one or more 
cardiovascular risk factors (in the case of sub-
jects who were 55 years of age or older) or known 
cardiovascular disease (in the case of subjects who 
were 50 years of age or older) (Section 2 in Sup-
plementary Appendix 1). Subjects were excluded 
if they had abnormal laboratory test results or 
concomitant conditions that could interfere with 
the assessment of the safety or efficacy of the 
study drug or if they had taken antidiabetic med-
ication within the previous 5 years.11
Study Medication
Participants were randomly assigned, with the use 
of an interactive voice-response telephone system, 
to nateglinide, at a dose of 60 mg taken before 
meals three times daily, or placebo and, in a 2-by-
2 factorial design, to valsartan or placebo. Both 
the participants and the investigators were un-
aware of the treatment assignments. Nateglinide 
was initially dispensed at a dose of 30 mg, with 
an increase to the full dose of 60 mg after 2 weeks. 
Reductions in the dose were permitted if there 
were side effects. The comparison of valsartan 
with placebo is reported elsewhere in this issue 
of the Journal.12 
Lifestyle Modification
All subjects were required to participate in a study-
specific lifestyle modification program that was 
designed to reduce the risk of diabetes (see Sec-
tion 3 in Supplementary Appendix 1). The aim of 
the program was to help participants achieve and 
maintain a 5% weight loss, reduce the amount of 
saturated and total fats in their diets, and in-
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crease their physical activity to 150 minutes week-
ly.5,6 To facilitate adherence, site personnel who 
were trained to administer the program provided 
materials to participants at each clinic visit and re-
inforcement through interim telephone contacts.
Study Procedures
After the dose-adjustment phase, participants re-
turned for study visits every 6 months. The fast-
ing plasma glucose level was measured every 6 
months for 3 years and annually thereafter. Oral 
glucose-tolerance tests were performed yearly. On 
the mornings of study visits, the administration 
of the study medication was delayed until after the 
glucose tests had been performed so that the glu-
cose measurements would not be affected by the 
study drugs.
Study Outcomes
Initially, there were two coprimary outcomes: in-
cident diabetes mellitus and an extended compos-
ite cardiovascular outcome (death from a cardio-
vascular cause, nonfatal myocardial infarction, 
nonfatal stroke, hospitalization for heart failure, 
arterial revascularization, or hospitalization for 
unstable angina). A third coprimary core cardio-
vascular outcome (death from a cardiovascular 
cause, nonfatal myocardial infarction, nonfatal 
stroke, or hospitalization for heart failure), which 
had initially been designated as a secondary out-
come, was added, as described previously.11,13
Diabetes was considered to be present14,15 if the 
participant had a fasting plasma glucose level of 
126 mg per deciliter or more or a glucose level of 
200 mg per deciliter (11.1 mmol per liter) or more 
2 hours after a glucose challenge — confirmed by 
an oral glucose-tolerance test within 12 weeks af-
ter the elevated glucose value was recorded. The 
date of the onset of diabetes was considered to be 
the date of the first elevated glucose value. An in-
dependent committee, whose members were un-
aware of the treatment assignments, adjudicated 
cases in which diabetes was diagnosed by other 
means. Participants in whom diabetes developed 
could have open-label antidiabetic medication — 
with the exception of prandial glucose regulators 
— added to their regimen.
Deaths, hospitalizations, and potential cardio-
vascular events that did not result in hospitaliza-
tion were adjudicated by an independent committee 
whose members were unaware of the treatment 
assignments. (Definitions of these outcomes are 
provided in Section 4 in Supplementary Appen-
dix 1.)
Statistical Analysis
The targeted sample size of 9152 participants was 
determined on the basis of the estimated number 
of participants that would be needed to provide 
the power required for the valsartan-versus-pla-
cebo component of the study.11,13 We estimated 
that diabetes would develop in at least 3000 of 
these participants, with the result that the study 
would have more than 99% power to detect a 25% 
reduction in the risk of incident diabetes.
Since the effects of the two drugs (nateglinide 
and valsartan) on the three coprimary outcomes 
were examined in a factorial manner, we adjusted 
for the three tests that were performed for each 
drug, but not across drugs. We report two-sided 
P values throughout, as well as protocol-specified 
one-sided values for the coprimary outcomes and 
their components. The 2.5% one-sided family-wise 
type I error rate for each drug was controlled with 
the use of a closed-testing procedure that initially 
assigned one fifth of the alpha to the diabetes 
outcome and four fifths to the two cardiovascular 
outcomes (since we anticipated that there would be 
more cases of diabetes than of cardiovascular out-
comes). This allowed for the testing of each copri-
mary outcome even if the others did not differ 
significantly between the study groups but would 
usually require a two-sided P value of less than 0.01 
for the difference in the diabetes outcome to be 
considered significant (Section 5 in Supplementary 
Appendix 1). An O’Brien–Fleming type of alpha 
spending approach accounted for the interim 
efficacy analysis that was performed in Novem-
ber 2005, when 30% of the target number of par-
ticipants had had an extended cardiovascular out-
come (one-sided alpha spent: 0.00004).16
Log-rank tests, stratified according to the pres-
ence or absence of a history of cardiovascular dis-
ease and to randomized assignment to valsartan 
or placebo, were used to compare the nateglinide 
and placebo groups with respect to the time to 
the first event in the extended or core cardiovas-
cular outcome. A Cox discrete-time proportion-
al-odds model17 was used to assess incident dia-
betes, given the fixed-time schedule for glucose 
measurements. We also performed predefined 
analyses of the components of the composite car-
diovascular outcome, exploratory outcomes (the 
time to death from all causes and the time to 
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cardiovascular-related hospitalization), indexes of 
hyperglycemia, and body weight. We tested for a 
possible interaction between valsartan and nat-
eglinide for each reported outcome. The effects 
of the study treatment were evaluated in pre-
specified subgroups (Section 6 in Supplementary 
Appendix 1).11 Baseline characteristics of the par-
ticipants, safety assessments, and additional mea-
surements during the trial were compared with 
the use of summary statistics.
R esult s
Study Participants 
Of 43,502 participants who were screened at 806 
centers in 40 countries, 9518 were randomly as-
signed to a study drug between January 4, 2002, 
and January 29, 2004. The most common reasons 
for exclusion were ineligibility (96.6%) and refusal 
to participate (2.5%). After randomization, 212 
participants at 10 sites were excluded when the 
sites were closed owing to deficiencies in the ad-
herence to Good Clinical Practice guidelines, leav-
ing 9306 participants whose data were included 
in the final analyses (Fig. 1).
Among participants who were taking the study 
drug at 6 months, fewer people in the nateglinide 
group than in the placebo group were taking the 
full dose of the study drug (92.0% vs. 94.2%, 
P<0.001). At 1 year, 79.8% of the surviving partici-
pants in the nateglinide group and 80.8% of those 
in the placebo group were still receiving the study 
medication (P = 0.26); the respective percentages 
were 74.7% and 75.9% at 3 years (P = 0.20) and 
69.9% and 71.0% at 5 years (P = 0.28).
The baseline characteristics of the nateglinide 
and placebo groups did not differ significantly 
(Table 1). Of the 9306 participants, 3547 (38.1%) 
reported that a primary relative had diabetes and 
2266 (24.3%) had known cardiovascular disease. 
There were no significant differences between 
the groups in concomitant treatments at base-
line or at study end. At study end, less than 3% 
of the participants in whom diabetes had not 
developed were taking open-label glucose-lower-
ing therapies.
Follow-up
The fasting plasma glucose level or the plasma 
glucose level 2 hours after a glucose challenge was 
measured at the closeout visit or during the final 
6 months of the study in 80% of the surviving 
participants who had not withdrawn consent and 
in whom diabetes had not developed. A total of 
609 participants in the nateglinide group (13.1%) 
and 602 in the placebo group (12.9%) were lost to 
follow-up or withdrew from the study; however, 
because many of these participants were lost to 
follow-up or withdrew consent late in the study, 
information on vital status was available for 95.7% 
of the possible follow-up time in both groups. 
The median follow-up time for data on vital status 
was 6.5 years, and the median follow-up times 
for data on the diabetes, extended cardiovascu-
lar, and core cardiovascular outcomes were 5.0, 
6.3, and 6.4 years, respectively. 
Study Outcomes 
Coprimary Diabetes Outcome
Diabetes developed in 1674 participants in the 
nateglinide group (36.0%) and in 1580 participants 
in the placebo group (33.9%) (hazard ratio with 
nateglinide, 1.07; 95% confidence interval [CI], 
1.00 to 1.15; P = 0.05) (Table 2 and Fig. 2A). The 
effect of nateglinide on the progression of im-
paired glucose tolerance to diabetes was consis-
tent across all prespecified subgroups except for 
subgroups specified according to sex and fasting 
plasma glucose level (Section 6A in Supplemen-
tary Appendix 1).
Coprimary Cardiovascular Outcomes
The extended composite cardiovascular outcome 
occurred in 658 participants in the nateglinide 
group (14.2%) and in 707 participants in the pla-
cebo group (15.2%) (hazard ratio with nategli-
nide, 0.93; 95% CI, 0.83 to 1.03; P = 0.16 (Table 2 
and Fig. 2B). The core composite cardiovascular 
outcome occurred in 365 participants in the na-
teglinide group (7.9%) and in 387 participants in 
the placebo group (8.3%) (hazard ratio with na-
teglinide, 0.94; 95% CI, 0.82 to 1.09; P = 0.43) (Ta-
ble 2 and Fig. 2C). Nateglinide treatment had no 
significant effect on the coprimary cardiovascu-
lar outcomes in any of the prespecified subgroups 
(Sections 6B and 6C in Supplementary Appendix 1).
Components of Primary Outcomes and Exploratory 
Outcomes
As shown in Table 2 and Figure 2D, there were 
no significant differences between the nateglin-
ide and placebo groups with respect to the com-
ponents of the extended cardiovascular compos-
ite outcome, including death from cardiovascular 
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causes, or with respect to the prespecified explor-
atory outcomes of hospitalization for a cardiovas-
cular cause and death from any cause. 
No interactions between nateglinide and val-
sartan were seen for any of the outcomes reported 
(Section 7 in Supplementary Appendix 1).
Glycemia
During the course of the study, participants in the 
nateglinide group had lower mean fasting plas-
ma glucose levels than did those in the placebo 
group; the mean difference was 0.47 mg per deci-
liter (95% CI, 0.05 to 0.90) (0.03 mmol per liter 
[95% CI, 0.003 to 0.05]) (P = 0.03) (Fig. 3A). How-
ever, glucose levels 2 hours after a glucose chal-
lenge were higher in the nateglinide group than 
in the placebo group; the mean difference was 
4.37 mg per deciliter (95% CI, 2.80 to 5.93) (0.24 
mmol per liter [95% CI, 0.16 to 0.33]) (P<0.001) 
(Fig. 3B).
In the two exploratory analyses we conducted, 
incident diabetes defined on the basis of fasting 
6 col
33p9
9518 Were randomly assigned to receive either
nateglinide or placebo
43,502 Patients with cardiovascular disease or 
cardiovascular risk factors were screened
39,282 (90.3%) Were screened once
4133 (9.5%) Were screened twice
87 (0.2%) Were screened three
or four times
32,984 Were excluded
24,023 Did not meet inclusion criteria for
impaired glucose tolerance or 
cardiovascular risk factors
6719 Had an abnormal laboratory value
1652 Had an abnormal test result
853 Withdrew consent
293 Had other reasons
215 Were ineligible owing to medical 
history
171 Were taking excluded medication
58 Had an intercurrent medical event
9306 Were included in the final analysis
212 Were excluded because
of protocol deficiencies at site
4645 Were assigned to receive nateglinide
(with or without valsartan)
4661 Were assigned to receive placebo
(with or without valsartan)
919 Discontinued




459 Were lost to follow-up
312 Died
143 Withdrew participation
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Figure 1. Enrollment and Follow-up of Study Participants.
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(N = 4661) P Value
Age — yr 63.7±6.8 63.8±6.9 0.68
Female sex — no. (%) 2368 (51.0) 2343 (50.3) 0.41
Race — no. (%)†
White 3854 (83.0) 3880 (83.2) 0.71
Black 120 (2.6) 116 (2.5)
Asian 310 (6.7) 303 (6.5)
Other 361 (7.8) 362 (7.8)
Weight — kg 83.6±17.2 83.6±17.2 0.96
Body-mass index‡ 30.5±5.4 30.5±5.4 0.45
Waist circumference — cm§ 101±14 101±14 0.72
Men 104±12 104±13
Women 98±14 98±14
Blood pressure while seated — mm Hg
Systolic 139.8±17.5 139.5±17.4 0.30
Diastolic 82.6±10.3 82.5±10.2 0.79
Cardiovascular risk factors — no. (%)
Any 4579 (98.6) 4607 (98.8) 0.22
Family history of premature heart disease 791 (17.0) 753 (16.2) 0.24
Current smoker 519 (11.2) 506 (10.9) 0.57
Hypertension 3608 (77.7) 3608 (77.4) 0.77
Left ventricular hypertrophy 135 (2.9) 133 (2.9) 0.83
Microalbuminuria 45 (1.0) 69 (1.5) 0.03
Reduced HDL cholesterol 443 (9.5) 449 (9.6) 0.89
Elevated non-HDL cholesterol 2047 (44.1) 2116 (45.4) 0.21
History of cardiovascular disease — no. (%)
Any 1140 (24.5) 1126 (24.2) 0.38
Myocardial infarction 569 (12.2) 524 (11.2) 0.08
Angina or positive stress test 404 (8.7) 412 (8.8) 0.99
Percutaneous coronary intervention 190 (4.1) 172 (3.7) 0.26
Multivessel coronary-artery bypass grafting 194 (4.2) 186 (4.0) 0.61
Intermittent claudication 46 (1.0) 52 (1.1) 0.69
Peripheral arterial stenosis 16 (0.3) 38 (0.8) 0.003
Lower-limb angioplasty or bypass surgery 56 (1.2) 54 (1.2) 0.80
Nontraumatic leg or foot amputation 1 (<0.1) 6 (0.1) 0.06
Stroke 133 (2.9) 142 (3.0) 0.67
Family history of diabetes mellitus — no. (%) 1793 (38.6) 1754 (37.6) 0.33
Plasma glucose — mmol per liter
Fasting 6.1±0.45 6.1±0.46 0.71
2 hr after glucose challenge 9.2±0.93 9.2±0.94 0.56
Glycated hemoglobin — % 5.8±0.45 5.8±0.48 0.06
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(N = 4661) P Value
Metabolic syndrome — no. (%)¶ 3897 (84.0) 3898 (83.6) 0.73
Lipids — mg/dl
Total cholesterol 210±41 210±43 0.87
HDL cholesterol 50±13 50±13 0.43
LDL cholesterol 126±36 127±38 0.96
Triglycerides 0.76
Median 151 150
Interquartile range 109–208 107–209
Creatinine — mg/dl 0.9±0.2 0.9±0.2 0.25
Estimated GFR — ml/min/1.73 m2‖ 80.3±18.6 81.1±19.0 0.04
Estimated GFR <60 ml/min/1.73 m2 — no. (%) 525 (11.3) 495 (10.6) 0.30
Ratio of urinary albumin (mg) to creatinine (g) 0.25
Median 7.1 7.1
Interquartile range 4.5–14.1 4.5–14.8
Medications — no. (%)**
ACE inhibitor
Baseline 330 (7.1) 346 (7.4) 0.42
Last study visit 729 (15.7) 745 (16.0) 0.64
Angiotensin-receptor blocker
Baseline 20 (0.4) 27 (0.6) 0.31
Last study visit 317 (6.8) 311 (6.7) 0.75
Alpha-blocker
Baseline 288 (6.2) 289 (6.2) 0.99
Last study visit 233 (5.0) 240 (5.1) 0.78
Aspirin or other antiplatelet drug
Baseline 1712 (36.9) 1713 (36.8) 0.92
Last study visit 2119 (45.6) 2114 (45.4) 0.91
Beta-blocker
Baseline 1872 (40.3) 1794 (38.5) 0.08
Last study visit 1913 (41.2) 1927 (41.3) 0.82
Calcium-channel blocker
Baseline 1519 (32.7) 1493 (32.0) 0.49
Last study visit 1674 (36.0) 1720 (36.9) 0.39
Diuretic
Baseline 1461 (31.5) 1499 (32.2) 0.48
Last study visit 1664 (35.8) 1755 (37.7) 0.07
Lipid-modulating drug
Baseline 1797 (38.7) 1780 (38.2) 0.70
Last study visit 2301 (49.5) 2358 (50.6) 0.25
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plasma glucose levels and adjudicated outcomes 
alone occurred in 775 of the participants in the 
nateglinide group (16.7%) and 877 of the partici-
pants in the placebo group (18.8%) (hazard ratio 
with nateglinide, 0.87; 95% CI, 0.79 to 0.96; 
P = 0.005). In contrast, incident diabetes defined on 
the basis of plasma glucose levels 2 hours after a 
glucose challenge and adjudicated outcomes alone 
occurred in 981 of the participants in the nategli-
nide group (21.1%) and 819 of the participants 
in the placebo group (17.6%) (hazard ratio with 
nateglinide, 1.24; 95% CI, 1.13 to 1.36; P<0.001). 
Mean (±SD) glycated hemoglobin levels, measured 
at the time the diagnosis of diabetes was made, 
were lower in the nateglinide group than in the 
placebo group (6.1±0.6% vs. 6.3±0.6%, P<0.001).
Weight and Blood Pressure
There was a reduction in mean body weight dur-
ing the study, with 10.1% of participants losing 
5% of their baseline weight by 6 months, but the 
mean body weight was higher among participants 
in the nateglinide group than among those in the 
placebo group throughout the course of the study 
(mean difference, 0.35 kg; 95% CI, 0.22 to 0.48; 
P<0.001) (Fig. 3C). Mean waist circumference was 
also higher in the nateglinide group than in the 
placebo group (Fig. 3D). No significant between-
group differences were seen in systolic or diastol-
ic blood pressure (Fig. 3E and 3F).
Adverse Events and Discontinuation  
of the Study Drug
A total of 520 participants in the nateglinide group 
(11.2%) and 485 in the placebo group (10.4%) dis-
continued the study drug owing to an adverse 
event (P = 0.23). Rates of adverse events did not dif-
fer significantly between the groups, except that 
more participants in the nateglinide group report-
ed hypoglycemia (mostly mild events) (911 par-
ticipants [19.6%], vs. 527 [11.3%] in the placebo 
group; P<0.001) (Section 8 in Supplementary Ap-
pendix 1).
Discussion
In our study, the addition of nateglinide therapy 
to a lifestyle modification program did not re-
duce the risk of diabetes or cardiovascular events 
among subjects with impaired glucose tolerance 
and cardiovascular disease or cardiovascular risk 
factors. In two large-scale studies of lifestyle in-
tervention, the rate of progression from impaired 






(N = 4661) P Value
Antidiabetic drug††
Baseline 2 (<0.1) 5 (0.1) 0.26
Last study visit 651 (14.0) 670 (14.4) 0.61
*  Plus–minus values are means ±SD. Cochran–Mantel–Haenszel tests were used in the analyses of categorical vari-
ables; F tests (variance ratio tests) were used in the analyses of continuous variables. Both tests were stratified ac-
cording to valsartan or placebo assignment and presence or absence of a history of cardiovascular disease, except for 
cardiovascular disease and cardiovascular risk factors, for which stratification was according to age (<55 years vs. ≥55 
years). To convert the values for glucose to milligrams per deciliter, divide by 0.05551. To convert the values for cho-
lesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter,  
multiply by 0.01129. To convert the values for creatinine to micromoles per liter, multiply by 88.4. ACE denotes angio-
tensin-converting enzyme, GFR glomerular filtration rate, HDL high-density lipoprotein, and LDL low-density lipo-
protein.
†  Race was reported by investigators.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
§  Waist circumference was adjusted for sex.
¶  The metabolic syndrome was defined according to International Diabetes Federation consensus worldwide definition 
of the metabolic syndrome.18 
‖  The estimated GFR was calculated with the use of the modified Modification of Diet in Renal Disease formula.19
** The last study visit was defined as the last time the investigator recorded that the patient had or had not been taking 
concomitant medication — either at the end-of-study visit or at the last recorded visit before the patient’s death or 
withdrawal from the study.
†† Among participants who did not have progression to diabetes according to the protocol-specified criteria, 3.1% in the 
nateglinide group and 2.4% in the placebo group were taking antidiabetic medication. Among those who did have 
progression to diabetes, 33.3% and 37.7% in the two groups, respectively, were taking antidiabetic medication.
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58%.5,6 Some pharmacologic interventions have 
also reduced the risk of diabetes: in the 3.3-year 
Study to Prevent Non–Insulin-Dependent Diabetes 
Mellitus (STOP-NIDDM; ClinicalTrials.gov num-
ber, NCT00629213), there was a 25% relative risk 
reduction with the alpha glucosidase inhibitor ac-
arbose7; in the 2.8-year Diabetes Prevention Pro-
gram (DPP; NCT00004992), there was a 31% re-
duction with the biguanide metformin6; and in the 
3-year Diabetes Reduction Assessment with Rami-
pril and Rosiglitazone Medication (DREAM) study 
(NCT00095654), there was a 62% reduction with 
the thiazolidinedione rosiglitazone.8 The preven-
tion or delay of diabetes with lifestyle interven-
tion or metformin therapy can persist for up to 
10 years.20 However, a 3-year study of the second-
generation sulfonylurea gliclazide, a long-acting 
insulin secretagogue, did not show any reduction 
in the progression from fasting hyperglycemia to 
diabetes.21 In addition, no reduction was seen with 
the first-generation sulfonylurea tolbutamide in 
an intention-to-treat analysis of the 10-year follow-
up data from the Malmöhus trial.22
The d-phenylalanine derivative nateglinide is 
a short-acting insulin secretagogue. When it is 
taken before meals, it reduces postprandial glu-
cose excursions (i.e., increases above the premeal 
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Figure 2. Kaplan–Meier Curves for the Coprimary and Two Exploratory Outcomes in the Nateglinide and Placebo Groups.
Panel A shows results for the coprimary outcome of incident diabetes, Panel B for the coprimary outcome of extended cardiovascular 
outcomes (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina, 
heart failure, or arterial revascularization), Panel C for the coprimary outcome of core cardiovascular outcomes (death from cardiovascu-
lar causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure), and Panel D for death from any cause and 
death from cardiovascular causes. All P values are one-sided except for those for exploratory outcomes, which are two-sided. I bars indi-
cate 95% confidence intervals.
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was hypothesized that nateglinide might reduce 
the risk of progression to diabetes by restoring 
a more physiologic insulin response to meals 
than that which occurs with sulfonylureas such 
as glyburide.24 In addition, by diminishing post-
prandial hyperglycemia, nateglinide could have 
a favorable effect on the risk of cardiovascular 
events, given the independent significant associa-
tion between elevated glucose levels after a glu-
cose challenge and cardiovascular disease,2 and 
given the reduced risk of myocardial infarction 
seen in the STOP-NIDDM trial.10 We found that 
nateglinide offers no protection from the progres-
sion of impaired glucose tolerance to diabetes or 
from the progression of cardiovascular disease, 
and possibly raises glucose levels after a glucose 
challenge. A trial evaluating the effect of acarbose, 
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Figure 3. Changes in Mean Plasma Glucose Levels, Weight, Waist Circumference, and Blood Pressure  
in the Nateglinide and Placebo Groups over the Course of the Study.
To convert the values for glucose to milligrams per deciliter, divide by 0.05551. I bars indicate standard errors.
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comes among patients with impaired glucose tol-
erance and cardiovascular disease is under way.25
In a pilot study, glucose values 2 hours after a 
glucose challenge were significantly reduced when 
nateglinide was taken immediately before the 
test.22 In the NAVIGATOR study, in which the 
study medication was withheld on mornings be-
fore oral glucose-tolerance testing, we observed 
elevated glucose values 2 hours after a glucose 
challenge. It is uncertain whether these elevated 
values reflect the immediate effect of withdrawal 
of nateglinide, which may be similar to the im-
mediate effect of withdrawal of gliclazide,21 or a 
long-term diminution in the beta-cell response to 
an acute glucose challenge. The former may be 
the case, since a 7-day study in which subjects ate 
a standardized test meal showed that postpran-
dial glucose levels did not rebound above baseline 
values on the day that nateglinide was with-
drawn.26 In addition, glycated hemoglobin levels 
that were measured when diabetes developed were 
lower in the nateglinide group than in the place-
bo group, suggesting that the higher glucose val-
ues 2 hours after a glucose challenge that were 
seen after withdrawal of nateglinide may be a 
short-term rather than a long-term effect. Further 
interpretation might be aided by the assessment 
of markers of beta-cell function or insulin resis-
tance, but peptide levels were not assayed, and 
samples from oral glucose-tolerance tests were not 
retained.
The lifestyle modification program seems to 
have had an effect, as evidenced by the weight loss 
in both study groups, but the mean body weight 
in the nateglinide group was 0.35 kg higher than 
that in the placebo group. The lower mean weight 
loss with nateglinide could be associated with a 
greater risk of diabetes, given the findings of the 
Diabetes Prevention Program, in which there was 
a 58% reduction in the risk of diabetes among 
the lifestyle-intervention subjects, who achieved 
a 5% weight loss over the course of 3 years6; how-
ever, formal modeling would be required to test 
this hypothesis.
Concerns about potential adverse cardiovascu-
lar effects of glucose-lowering agents, particularly 
in persons with cardiovascular disease or at high 
risk for cardiovascular disease, have led the Food 
and Drug Administration to require cardiovascu-
lar-outcome studies for new antidiabetic agents.27 
In this respect, nateglinide appears to be safe in 
persons with impaired glucose tolerance, although 
the risk of hypoglycemia is increased.
The results of the NAVIGATOR trial show that 
among persons with impaired glucose tolerance 
and cardiovascular disease or cardiovascular risk 
factors, assignment to nateglinide, at a dose of 
60 mg three times daily, as compared with pla-
cebo, in addition to a lifestyle modification pro-
gram, did not reduce the incidence of diabetes or 
cardiovascular outcomes.
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